ArticleMedicine2018

The research status of immune checkpoint blockade by anti-CTLA4 and anti-PD1/PD-l1 antibodies in tumor immunotherapy in China: A bibliometrics study.

Xiaoqin Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.